LuxCath said today its catheter-based ablation device was used in its 1st procedure to treat arrhythmia patients, including patients with atrial fibrillation. The surgeries were led by Mount Sinai Hospital arrhythmia services director Dr. Vivek Reddy.
LuxCath’s catheter-based ablation device can assess tissue contact, visualize lesions and detect lesion gaps in real time, the company said. The technology has market applications in all arrhythmia ablation procedures and is optimized for the treatment of atrial fibrillation, LuxCath said.
“We are thrilled with the performance of our optical tissue interrogation system for contact and lesion progression assessment. Given the potential to positively impact all ablation procedures, we are excited to advance the technology into the marketplace. This is an enormous milestone for the company,” CEO Dr. Omar Amirana said in a prepared statement.
A total of 11 patients were treated with the ablation device in Prague’s Homolka Hospital, Boston-based LuxCath said.
“In all 11 patients, the technology identified tissue contact and was easy to use. In a wide variety of settings, we were able to assess and monitor ablation lesions as they were being created. There were no complications. This is an exciting step forward in the world of ablation. Based on our experience, the technology platform is quite promising,” Reddy said in a press release.
LuxCath said its optical tissue interrogation technology can be incorporated into standard ablation catheters at “very low costs with excellent yields,” according to a press release.
The company claims no other technology embedded into ablation catheters currently provides data or information about the tissue under the surface of the heart being ablated in real time.